Hubbry Logo
Permanent cellPermanent cellMain
Open search
Permanent cell
Community hub
Permanent cell
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Permanent cell
Permanent cell
Permanent cell
View on Wikipedia
from Wikipedia

Permanent cells are cells that are incapable of regeneration. These cells are considered to be terminally differentiated and non-proliferative in postnatal life. This includes neurons, heart cells, skeletal muscle cells[1].[2] Although these cells are considered permanent in that they neither reproduce nor transform into other cells, this does not mean that the body cannot create new versions of these cells. For instance, structures in the bone marrow produce new red blood cells constantly, while skeletal muscle damage can be repaired by underlying satellite cells, which fuse to become a new skeletal muscle cell.[3]

Culture of rat brain cells stained with antibody to MAP2 (green), Neurofilament NF-H (red) and DNA (blue). MAP2 is found in neuronal dendrites, while the neurofilament is found predominantly in axons. Antibodies and image courtesy of EnCor Biotechnology

Disease and virology studies can use permanent cells to maintain cell count and accurately quantify the effects of vaccines.[1] Some embryology studies also use permanent cells to avoid harvesting embryonic cells from pregnant animals; since the cells are permanent, they may be harvested at a later age when an animal is fully developed.[4]

See also

[edit]
  • Labile cells, which multiply constantly throughout life
  • Stable cells, which only multiply when receiving external stimulus to do so

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Permanent cell

View on Grokipedia
from Grokipedia
A permanent cell, also referred to as a post-mitotic or terminally differentiated cell, is a mature in multicellular organisms that has permanently exited the and lost the capacity for division or proliferation, even in response to or stress. These cells are characterized by their inability to undergo , distinguishing them from other cell populations that can regenerate through division. In the classification of tissues based on regenerative potential, permanent cells form a key category alongside labile cells (which continuously proliferate, such as epithelial cells) and cells (which divide only when needed, such as hepatocytes in the liver). Permanent cells include neurons in the , cardiomyocytes in the heart, and fibers, which maintain long-term function but cannot replace themselves if damaged. This limited regenerative ability has significant implications for tissue repair: damage to permanent cell-containing tissues, such as in or neuronal injury, typically results in and formation rather than full restoration of original and function, potentially leading to chronic conditions like or neurodegeneration. into therapies and continues to explore ways to overcome this barrier, though permanent cells remain inherently non-proliferative by design to support specialized roles in .

Definition and Characteristics

Definition

Permanent cells are terminally differentiated cells that are incapable of undergoing or proliferation in postnatal life. These cells arise from or stem cells during development, which initially possess the ability to divide and differentiate, but upon achieving maturity, they irreversibly lose their replicative capacity. In contrast to embryonic stages, where precursor cells may perform a limited number of divisions before attaining terminal differentiation, permanent cells in adults exhibit a stable, non-dividing state postnatally. This distinction underscores the developmental transition from proliferative potential to specialized function without renewal. The core mechanism underlying this non-proliferative state involves a permanent exit from the , often enforced by the upregulation of inhibitors such as the cyclin-dependent kinase inhibitor p21 and the (Rb). These proteins suppress and , ensuring the maintenance of cellular specialization.

Key Characteristics

Permanent cells, also known as post-mitotic or terminally differentiated cells, exhibit highly specialized morphological features that prioritize long-term functional stability over proliferative capacity. These cells develop intricate structural adaptations, such as extensive dendritic arborizations in neurons for signal integration or intercalated discs in cells for synchronized contraction, which enhance their efficiency in specialized roles while rendering them incapable of division. These morphological traits arise during terminal differentiation, where cells invest resources in structural complexity rather than maintaining a proliferative state, as seen in the formation of multinucleated myotubes in . At the molecular level, permanent cells are characterized by the upregulation of differentiation-specific genes and the downregulation of regulators, ensuring irreversible exit from the mitotic cycle. For instance, transcription factors like NeuroD promote neuronal differentiation by activating genes for structural proteins, while cyclin-dependent kinase inhibitors (CKIs) such as p21 and p27 accumulate to suppress and cyclin E activity, blocking the through Rb-family-mediated repression and . This molecular profile, including persistent formation via HP1α and the DREAM complex, maintains quiescence and prevents aberrant re-entry into the , distinguishing permanent cells from labile or stable proliferative types. Permanent cells achieve longevity spanning decades through robust maintenance mechanisms, including enhanced for protein and organelle turnover, and efficient pathways to counteract accumulated damage in non-dividing states. , involving proteins like Atg7 and LC3, clears dysfunctional components to sustain viability, while systems—such as predominant in post-mitotic contexts—address oxidative and replication-independent lesions, though inefficiencies can lead to . However, these cells remain vulnerable to if repair fails, as unrepaired DNA damage triggers p53-mediated pathways without the option for dilution through division. To meet their elevated energy demands without proliferative turnover, permanent cells rely on a high density of mitochondria optimized for , supporting intense metabolic activity such as synaptic transmission in neurons or continuous contraction in muscle. This mitochondrial abundance, accounting for up to 20% of the body's in neural tissues, ensures ATP production but heightens sensitivity to dysfunction, underscoring the for functional specialization.

Cell Proliferation Types

Labile Cells

Labile cells represent a category of continuously dividing cell populations that maintain tissue integrity by perpetually replacing cells lost through normal wear, injury, or . These cells exhibit a high capacity for throughout an organism's life, driven by activity that replenishes differentiated progeny. Prominent examples include the epithelial cells of the skin, the mucosal lining of the , and hematopoietic s in the , which generate lineages to sustain systemic functions. The proliferative capacity of labile cells is characterized by a high , reflecting frequent entry into the and progression through its phases—G1, S, G2, and M—under the influence of mitogenic signals. Growth factors such as (EGF) play a central role in stimulating this process by binding to cell surface receptors, thereby activating intracellular pathways that promote and division. This ongoing proliferation ensures rapid replacement of short-lived cells, with lifespans typically ranging from days to weeks, contrasting sharply with the post-mitotic nature of permanent cells. Tissue turnover rates among populations underscore their role in and repair. In the bone marrow, hematopoietic stem cells produce approximately 500 billion new blood cells daily to maintain circulating levels. epithelial cells renew every 40–56 days, allowing the to shed and regenerate its outer layers continuously. Similarly, intestinal mucosal epithelial cells turn over every 4–5 days, facilitating amid constant exposure to luminal contents. Regulation of labile cell proliferation involves intricate checkpoints and signaling mechanisms to balance renewal with prevention of uncontrolled growth, such as in oncogenesis. The restriction point in G1 phase commits cells to division only upon sufficient growth factor stimulation, while intra-S and G2/M checkpoints monitor DNA integrity to halt progression if damage is detected. These controls, including tumor suppressor pathways, mitigate risks of overproliferation in high-turnover tissues like the gut mucosa and hematopoietic system.

Stable Cells

Stable cells, also known as quiescent or conditionally renewing cells, are those that normally reside in a non-proliferative state within the G0 phase of the cell cycle but retain the capacity to re-enter the cell cycle and proliferate in response to specific stimuli such as injury or increased physiological demand. Unlike permanent cells, which enter an irreversible G0 state and lose proliferative potential entirely, stable cells maintain latent mitotic competence. Prominent examples include hepatocytes in the liver, proximal renal tubular epithelial cells, and endothelial cells lining blood vessels, which typically remain dormant under homeostatic conditions but can activate to support tissue maintenance or repair. Activation of stable cells occurs through extracellular signals, including s and hormones, that promote progression from G0 to the and subsequent . For instance, growth factor (HGF), produced by non-parenchymal liver cells and mesenchymal tissues, binds to the c-MET receptor on hepatocytes, initiating signaling cascades such as PI3K/AKT and MAPK/ERK pathways that drive limited rounds of division, often 1-2 cycles, after which the cells return to quiescence. Similarly, renal tubular cells and endothelial cells respond to injury-induced factors like (VEGF), which enhances their survival and proliferative response while mitigating . These cells demonstrate significant regeneration potential through , enabling tissue restoration without relying on differentiation. A classic example is in mammals following partial , where the remnant liver lobes undergo compensatory growth to restore 70-80% of the original mass within 7-10 days, primarily via proliferation rather than precursor activation. This process highlights the adaptive hyperplasia of stable cells, allowing organs like the liver and to recover function after acute insults such as exposure or ischemia. However, the proliferative capacity of stable cells is constrained by a finite replicative lifespan, primarily due to progressive shortening with each division, which eventually triggers and limits long-term renewal in contrast to the continuous turnover of labile cells. This attrition imposes a biological barrier, ensuring that while stable cells can mount robust short-term responses, they cannot sustain indefinite proliferation without external interventions like telomerase activation.

Comparison to Permanent Cells

Permanent cells represent the endpoint of the proliferation spectrum among tissue cell types, exhibiting no capacity for division in adulthood, in contrast to labile cells, which continuously proliferate to maintain tissues like the skin and gastrointestinal epithelium, and stable cells, which remain quiescent but can re-enter the in response to stimuli, as seen in the liver and kidneys. This classification, based on regenerative potential, underscores the post-mitotic commitment of permanent cells, such as neurons and cardiac myocytes, which exit the cell cycle permanently after differentiation. The non-proliferative state of permanent cells is maintained through epigenetic mechanisms that silence proliferation-associated genes, preventing re-entry into the . For instance, in cardiac myocytes, the proteins Rb and p130 recruit complexes to repress E2F-dependent genes, ensuring stable silencing via modifications and . Similarly, in neurons, epigenetic repression of cyclin-dependent kinases and other mitotic regulators locks cells in a differentiated, non-dividing configuration, prioritizing long-term functional stability over renewal potential. This commitment to a post-mitotic state imposes functional s, where permanent cells achieve high specialization for roles like rapid in the but become vulnerable to irreversible loss upon injury, as replacement relies solely on surviving cells or supportive rather than self-renewal. In evolutionary terms, the emergence of such non-regenerative cells in mammals may reflect a favoring enhanced tumor suppression and metabolic in complex tissues, at the expense of regenerative capacity, allowing for the development of intricate structures like the while reducing cancer risk from unchecked division. Histologically, these differences manifest quantitatively: permanent cell tissues display zero mitotic figures under normal conditions, reflecting absent proliferation, whereas labile tissues exhibit frequent mitoses (often >1 per in active areas), and stable tissues show rare or stimulus-induced figures (typically <0.1 per field). This absence of mitotic activity in permanent cells highlights their terminal differentiation and informs pathological assessments of tissue repair limitations.

Examples in Human Physiology

Neurons

Neurons serve as the quintessential example of permanent cells within the , characterized by their terminally differentiated, post-mitotic state that precludes throughout adulthood. These cells are essential for information processing and transmission, forming the structural and functional backbone of the central and peripheral nervous systems. Unlike proliferative glial cells, neurons exit the permanently after differentiation, relying on their longevity to maintain neural circuits. The structure of neurons reflects their specialization for signal propagation, typically exhibiting a multipolar morphology with a central cell body (soma), multiple branching dendrites, a single elongated , and synaptic terminals. Dendrites receive incoming signals, the axon conducts outgoing impulses over long distances, and synapses facilitate communication with other cells via release. Mature neurons lack centrioles, a key feature contributing to their inability to undergo , as centrioles are required for spindle formation during . Functionally, neurons are optimized for electrochemical signaling, generating and propagating action potentials to enable rapid communication across neural networks. In the , approximately 86 billion neurons form intricate connections, with the vast majority generated prenatally during embryonic and early postnatal development. Neurons originate from neural cells in the developing neuroepithelium, undergoing proliferation before differentiating into post-mitotic states by birth. While most neurons are produced during this period and do not divide thereafter, limited occurs in restricted regions such as the hippocampal , generating new granule cells that integrate into existing circuits but insufficient to offset widespread losses. This non-replicative nature renders neurons particularly vulnerable to neurodegenerative diseases, such as Alzheimer's and Parkinson's, where irreversible loss of specific neuronal populations leads to progressive dysfunction without effective replacement. The inability to regenerate amplifies damage from stressors like and oxidative injury, underscoring the fragility of these long-lived cells.

Cardiac Muscle Cells

Cardiac muscle cells, or cardiomyocytes, exhibit a distinctive branched and striated morphology, featuring sarcomeres as the fundamental contractile units composed of overlapping and filaments that enable forceful contractions. These cells are interconnected by specialized intercalated discs, which include gap junctions for rapid electrical impulse propagation and desmosomes for mechanical stability, thereby forming a functional that ensures coordinated, wave-like contractions across the myocardium. Approximately 25% of cardiomyocytes are binucleated, a feature that emerges during development and persists throughout life without altering the post-mitotic state of the cells. Functionally, cardiomyocytes drive the involuntary, rhythmic contractions essential for systemic circulation, with the adult human heart comprising roughly 2 billion such cells that occupy 75-80% of the myocardial volume despite representing only 20-40% of total cardiac cells by number. Postnatally, cardiomyocyte addition is minimal, with annual turnover rates below 1% in adulthood, reinforcing their classification as permanent cells incapable of significant self-renewal. This fixed population supports efficient ATP-dependent contractions fueled primarily by aerobic metabolism of fatty acids and glucose, allowing the heart to pump approximately 7,000 liters of blood daily under autonomic control.00576-0) During development, cardiomyocytes arise from mesodermal cells, particularly those in the first and second heart fields, which differentiate into contractile myocardium starting around the third week of human through regulated signaling pathways involving BMP, FGF, and WNT. Terminal differentiation occurs predominantly within the first week after birth, after which cells exit the and cease proliferation, shifting reliance for cardiac growth to hypertrophy of existing cardiomyocytes rather than . This developmental trajectory establishes the heart's mature syncytial architecture by the late fetal to early postnatal period. Physiologically, cardiomyocytes integrate seamlessly with pacemaker cells in the sinoatrial and atrioventricular nodes to sustain the heart's intrinsic rhythmic beating at 60-100 beats per minute at rest, propagating action potentials via the syncytial network for efficient ventricular and . However, their permanent, non-regenerative nature means that injury, such as ischemia, results in followed by fibrotic replacement by non-contractile from activated fibroblasts, impairing long-term cardiac function and contributing to conditions like .

Skeletal Muscle Cells

Skeletal muscle cells, also known as muscle fibers or myofibers, are elongated, cylindrical cells that form multinucleated syncytia through the fusion of multiple myoblasts during development. These syncytia contain hundreds to thousands of myofibrils, which are organized bundles of contractile proteins including and filaments arranged into repeating sarcomeres, enabling the striated appearance and precise contraction characteristic of . The , or , surrounds each fiber, with nuclei positioned peripherally, and the fibers are bundled into fascicles encased by connective tissues such as endomysium, perimysium, and for structural support. These cells are primarily responsible for voluntary movements, posture maintenance, and force generation in the body, distinguishing them from the involuntary contractions of cardiac muscle cells. Comprising approximately 40% of total body weight in humans, skeletal muscle fibers collectively enable locomotion and manipulation of the environment through neural control from the somatic nervous system. Postnatally, these fibers do not proliferate but are supported by satellite cells, which contribute to repair and adaptation without forming new fibers. Skeletal muscle development, or , begins in embryogenesis with progenitor cells differentiating into myoblasts that fuse to form primary and secondary myofibers, a process mediated by fusogenic proteins such as myomaker and myomerger. By birth, is largely complete, with fibers specializing into slow-twitch (type I) or fast-twitch (type II) variants based on contractile properties. Postnatal growth occurs through , where existing fibers increase in size via the addition of myofibrils and myonuclei from cell fusion, rather than . Maintenance of fibers relies on continuous protein synthesis to preserve integrity and contractile function, as these post-mitotic cells cannot regenerate by dividing. The core structure of each fiber remains irreplaceable throughout life, with adaptations to stress or injury achieved through or limited contributions from satellite cells that add nuclei but do not replace lost fibers.

Physiological Implications

Regeneration Limitations

Permanent cells, such as neurons and cells, exhibit profound limitations in regeneration due to intrinsic and extrinsic biological barriers that prevent and tissue repair. Intrinsically, these cells enter a post-mitotic state early in development, characterized by the absence of functional mitotic machinery and a stable nuclear architecture, including the , which inhibits re-entry into the ; attempts to induce proliferation often lead to rather than division. In cells, additional barriers include arrest and polyploidization, which further restrict proliferative potential. maintenance issues exacerbate these limitations, as progressive telomere shortening in somatic cells induces in post-mitotic cells, impairing cellular function and any potential regenerative response. Extrinsically, the microenvironment post-injury becomes inhibitory; in the , glial scar tissue forms a physical and chemical barrier that suppresses axonal regrowth and neuronal replacement, while in the heart, fibrotic scarring replaces lost myocardium and hinders functional recovery. At the tissue level, the inability of permanent cells to regenerate results in lasting functional deficits. Loss of neurons following ischemic stroke causes irreversible brain damage and permanent neurological impairments, such as motor and sensory deficits, due to the failure of surviving neurons to compensate for the lost population. Similarly, myocardial infarction in leads to extensive cardiomyocyte , followed by scar formation that weakens the ventricular wall and predisposes to complications like left ventricular aneurysms, where thinned bulges under pressure, impairing contractility and increasing risk. In contrast to labile tissues, such as the skin epidermis, where continuous enables full regeneration and restoration of function after , damage to permanent cell-containing tissues results in incomplete repair, chronic scarring, and progressive functional decline without cellular replacement. These limitations manifest in quantifiable age-related impacts, particularly in sensory systems; for instance, olfactory bulb s exhibit minimal turnover, with an estimated annual replacement rate of only about 0.008%, leading to uncompensated loss over time that contributes to the widespread olfactory decline observed in over 50% of individuals aged 65 and older.

Compensatory Mechanisms

When permanent cells are lost, the body employs of surviving cells as a primary compensatory mechanism to maintain tissue function. , following , the remaining cardiomyocytes undergo adaptive , enlarging to increase contractile force and normalize ventricular wall stress, thereby preserving in the short term. This process involves molecular regulators such as the lncRNA Sweetheart, which promotes thickening and enhances cell size in response to hypoxic stress. Similarly, in , surviving myofibers can to compensate for fiber loss, supported by auxiliary cells that bolster structural integrity. Auxiliary cells play a crucial role in providing indirect support to permanent cells after damage. In the , glial cells such as and extend processes to neighboring territories, clearing neuronal debris through and offering metabolic and synaptic support to mitigate the impact of loss. This glial multitasking maintains blood-brain barrier integrity and regulates synaptic activity, compensating for dysfunctional or neuronal injury without replacing lost neurons. In , fibroblasts produce components like collagens I, III, and IV, which provide mechanical stability and facilitate force transmission from remaining myofibers to tendons, aiding structural compensation post-injury. Neuroplasticity enables functional redistribution in the following permanent loss, primarily through synaptic rewiring and circuit reorganization. After or neuronal damage, surviving neurons form new connections via axonal sprouting and enhanced synaptic strength in peri-infarct regions, such as increased density in cortical layer V, allowing contralesional areas to assume lost functions. This adaptive plasticity occurs in phases, with rapid early improvements followed by slower consolidation, often enhanced by rehabilitative training to redistribute motor or cognitive tasks. These compensatory mechanisms offer only temporary efficacy, as chronic or repeated cell loss overwhelms adaptations, leading to . In the heart, sustained alters calcium handling—prioritizing diastolic control at the expense of systolic dynamics—eventually contributing to and after multiple infarcts. Similarly, prolonged neuronal loss diminishes neuroplasticity's capacity for rewiring, resulting in progressive neurodegeneration, while excessive activity in muscle can lead to and impaired contractility.

Research and Clinical Relevance

Historical Context

In the mid-19th century, histologists began using light microscopy to examine tissue structures, leading to early observations of non-dividing cells in the . , a pioneer in cellular , distinguished neurons from glial cells through his studies of brain tissue, noting their morphological differences and contributing to the view of specialized, stable cell types in multicellular organisms. These findings, published in his 1858 work Die Cellularpathologie, aligned with the emerging . By the , embryological research further clarified the developmental origins of . Wilhelm His, through serial sectioning of human embryos, demonstrated that neurons originate from cells lining the and migrate to form the , becoming differentiated units. Concurrently, Santiago Ramón y Cajal's application of Camillo Golgi's silver staining technique provided histological evidence for the neuron doctrine, portraying neurons as discrete, independent cells that do not regenerate through division after development. Cajal's publications argued that this fixed state underscores the nervous system's reliance on precise embryonic patterning rather than ongoing cellular proliferation. These observations aligned with broader theoretical shifts from —which attributed life's processes to an immaterial force without cellular specificity—to the cell theory's mechanistic framework. Formulated by and Matthias Schleiden in 1838–1839 and extended by Virchow's 1855 dictum omnis cellula e cellula, the theory established cells as the fundamental units of life arising from preexisting cells, positioning differentiated cells like neurons as endpoints of developmental lineages. This integration reframed around cellular autonomy and specialization, diminishing vitalistic explanations for tissue stability. A key milestone in confirming the post-mitotic state came in the 1950s with electron microscopy advancements. Studies by Sidney Palay and colleagues revealed the of , providing insights into their mature, stable morphology that supported the concept of terminally differentiated entities. This structural validation bridged early histological insights with modern cytology.

Modern Therapeutic Approaches

Modern therapeutic approaches to address the limitations of permanent cells, such as and cells, primarily involve stem cell-based regeneration and technologies to restore function or induce proliferation where natural repair is absent. Induced pluripotent stem cells (iPSCs) have emerged as a key tool for replacement, particularly in neurodegenerative diseases like Parkinson's, where dopaminergic precursors derived from iPSCs are transplanted to replenish lost cells. In the 2020s, multiple clinical trials have advanced this strategy; for instance, a Phase I/II trial initiated in in 2025 (jRCT2090220384) demonstrated that allogeneic iPSC-derived progenitors survived implantation, produced , and showed no tumor formation in Parkinson's patients after one year. Similarly, two Phase I and II trials reported in 2025 evaluated the safety and efficacy of transplanting early-stage dopamine-producing cells, yielding preliminary improvements in motor symptoms without severe adverse events. Another ongoing trial, NCT06482268, assesses the safety of iPSC-derived progenitors in advanced Parkinson's cases, focusing on incidence and severity of treatment-emergent adverse events. Gene editing techniques, notably activation (a), target genes to promote cardiovascular formation or correct mutations in post-mitotic cardiac cells for myocardial repair. In the , foundational studies in mice used / to edit genes like PRKAG2, correcting mutations in postnatal hearts and restoring normal cardiac function without off-target effects. More recent applications of a have reprogrammed fibroblasts into cardiovascular progenitors by activating endogenous genes such as Mef2c and Gata4, promoting improved heart function in mouse models of . These approaches build on studies from the late , including 2017 experiments demonstrating editing in cardiomyocytes, offering proof-of-concept for genetic interventions in non-regenerative mammalian hearts. For fibers, another type of permanent cell, research as of 2025 explores editing and cell therapies to address damage in conditions like . CRISPR-based approaches have targeted mutations in preclinical models, with early-phase trials evaluating of edited myoblasts for transplantation. Despite these advances, challenges persist, including immune rejection of transplanted cells, which can trigger innate and adaptive responses leading to graft failure in allogeneic therapies. Strategies to mitigate rejection, such as hypoimmunogenic iPSC derivatives, have shown promise in preclinical models by evading host immune detection. Insights from models, which achieve partial heart regeneration through epicardial activation and cardiomyocyte post-injury, have informed human trial designs by identifying pathways like signaling essential for tissue repair. These models highlight conserved mechanisms that could enhance mammalian regeneration, guiding ongoing efforts to translate findings into clinical applications. As of 2025, clinical status includes FDA-approved neural prosthetics serving as interim bridges for permanent cell damage, such as devices for Parkinson's that modulate neural circuits to alleviate symptoms. For , several Phase II trials are underway, including a 2025 multicenter study evaluating intrathecal anti-Nogo-A antibodies, which improved function in tetraplegic patients compared to . Another Phase II trial assesses combined mesenchymal stem cells and Schwann cells for relief in complete injuries, reporting enhanced sensory recovery without major safety concerns.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK582256/
  2. https://pathologia.ed.ac.uk/topic/wound-healing-regeneration-and-scarring/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8474720/
  4. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/permanent-cell
  5. https://www.sciencedirect.com/science/article/pii/B9780080552941001847
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4825819/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC2175169/
  8. https://www.nature.com/articles/s41418-022-00988-z
  9. https://doi.org/10.1016/j.devcel.2007.02.020
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC2700000/
  11. https://doi.org/10.1038/sj.emboj.7601789
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC3986830/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8581214/
  14. https://www.pnas.org/doi/10.1073/pnas.1917280117
  15. https://www.mdpi.com/1422-0067/23/5/2484
  16. https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.14298
  17. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-024-00409-w
  18. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/labile-cell
  19. https://teachmephysiology.com/histology/tissue-structure/cellular-adaptations/
  20. https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Physiology/Labile_cells/
  21. https://www.bocsci.com/resources/growth-factors-for-mammalian-cell-culture.html
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC8699227/
  23. https://pubmed.ncbi.nlm.nih.gov/23315278/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2861991/
  25. https://pubmed.ncbi.nlm.nih.gov/18808327/
  26. https://www.ncbi.nlm.nih.gov/books/NBK6318/
  27. https://www.khanacademy.org/science/biology/cellular-molecular-biology/stem-cells-and-cancer/a/cell-cycle-checkpoints-article
  28. https://jeccr.biomedcentral.com/articles/10.1186/s13046-016-0433-9
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7665062/
  30. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/stable-cell
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC3081175/
  32. https://journals.physiology.org/doi/full/10.1152/ajprenal.2000.278.6.F905
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC2797862/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC6356700/
  35. https://www.nature.com/articles/s41556-022-00842-x
  36. https://www.sciencedirect.com/topics/medicine-and-dentistry/labile-cell
  37. https://rupress.org/jcb/article/194/3/407/36612/Rb-and-p130-control-cell-cycle-gene-silencing-to
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC4219506/
  39. https://www.sciencedirect.com/science/article/pii/S0092867421012848
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC3105469/
  41. https://medcell.org/tbl/tissue_remodeling/reading.php
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3376047/
  43. https://www.sciencedirect.com/science/article/abs/pii/S0168010200001012
  44. https://www.ncbi.nlm.nih.gov/books/NBK441977/
  45. https://qbi.uq.edu.au/brain/brain-anatomy/types-neurons
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC3271965/
  47. https://www.pnas.org/doi/10.1073/pnas.1201895109
  48. https://link.springer.com/article/10.1007/s11065-010-9148-4
  49. https://www.cell.com/fulltext/S0092-8674%2816%2931404-0
  50. https://www.sciencedirect.com/science/article/pii/S0896627311005617
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC4514105/
  52. https://www.ncbi.nlm.nih.gov/books/NBK572070/
  53. https://www.nejm.org/doi/full/10.1056/NEJM200106073442303
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC3963760/
  55. https://www.nature.com/articles/s41392-024-02069-8
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC4768311/
  57. https://www.ncbi.nlm.nih.gov/books/NBK537236/
  58. https://www.ncbi.nlm.nih.gov/books/NBK537139/
  59. https://pubmed.ncbi.nlm.nih.gov/25294644/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC11234433/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC6581816/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC10699255/
  63. https://www.embopress.org/doi/full/10.15252/embj.2018100492
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC8058361/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC8711586/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC3887360/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC9551642/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC11106628/
  69. https://www.cell.com/neuron/pdf/S0896-6273%2812%2900341-8.pdf
  70. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2014.00020/full
  71. https://www.nature.com/articles/s41467-023-42760-y
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC11418964/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC5079803/
  74. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.01023/full
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC5471387/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC11584505/
  77. https://embryo.asu.edu/pages/rudolf-carl-virchow-1821-1902
  78. https://pubmed.ncbi.nlm.nih.gov/30134065/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC10910026/
  80. https://www.britannica.com/science/cell-theory
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC2223597/
  82. https://www.nature.com/articles/s41586-025-08700-0
  83. https://www.parkinson.org/blog/science-news/cell-replacement
  84. https://clinicaltrials.gov/study/NCT06482268
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC8753567/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC5689453/
  87. https://www.nature.com/articles/s41591-024-02981-5
  88. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2824%2900447-2/fulltext
  89. https://pubmed.ncbi.nlm.nih.gov/39874104/
Add your contribution
Related Hubs
User Avatar
No comments yet.